Cited by 899Cancer-related Molecular PathwaysHeat shock proteins researchChromatin Remodeling and Cancer

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2

Open access

Kamijo, Takehiko, Weber, Jason D., Zambetti, Gerard, Zindy, Frederique, Roussel, Martine F., Sherr, Charles J.·1998·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.95.14.8292PMC PMC20969

Open this paper in CoChat — free account

Abstract

The INK4a-ARF locus encodes two proteins, p16(INK4a) and p19(ARF), that restrain cell growth by affecting the functions of the retinoblastoma protein and p53, respectively. Disruption of this locus by deletions or point mutations is a common event in human cancer, perhaps second only to the loss of p53. Using insect cells infected with baculovirus vectors and NIH 3T3 fibroblasts infected with ARF retrovirus, we determined that mouse p19(ARF) can interact directly with p53, as well as with the p53 regulator mdm2. ARF can bind p53-DNA complexes, and it depends upon functional p53 to transcriptionally induce mdm2 and the cyclin-dependent kinase inhibitor p21(Cip1), and to arrest cell proliferation. Binding of p19(ARF) to p53 requires the ARF N-terminal domain (amino acids 1-62) that is necessary and sufficient to induce cell cycle arrest. Overexpression of p19(ARF) in wild type or ARF-null mouse embryo fibroblasts increases the half-life of p53 from 15 to approximately 75 min, correlating with an increased p53-dependent transcriptional response and growth arrest. Surprisingly, when overexpressed at supra-physiologic levels after introduction into ARF-null NIH 3T3 cells or mouse embryo fibroblasts, the p53 protein is handicapped in inducing this checkpoint response. In this setting, reintroduction of p19(ARF) restores p53's ability to induce p21(Cip1) and mdm2, implying that, in addition to stabilizing p53, ARF modulates p53-dependent function through an additional mechanism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.95.14.8292

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells
Gorman, C., Moffat, L. F., & Howard, B. H. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.9.1044 · Cited by 7,674
High-Efficiency Transformation of Mammalian Cells by Plasmid DNA
Chen, C., & Okayama, H. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2745 · Cited by 5,327
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citation
QUANTITATIVE STUDIES OF THE GROWTH OF MOUSE EMBRYO CELLS IN CULTURE AND THEIR DEVELOPMENT INTO ESTABLISHED LINES
Todaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,747
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100

Flagged first, then by citations

Show all 61 references

Research works printed but not linked: 10

M Hollstein, K Rice, M S Greenblatt, T Soussi, R Fuchs, T Sorlie, E Hovig, B Smith-Sorensen, R Montesano, C C Harris Nucleic Acids Res 22, 3551–3555 (1994).
D Duro, O Bernard, V Della Valle, R Berger, C-J Larsen Oncogene 11, 21–29 (1995).
L Mao, A Merlo, G Bedi, G I Shapiro, C D Edwards, B J Rollins, D Sidransky Cancer Res 55, 2995–2997 (1995).
S Stone, P Jiang, P Dayananth, S V Tavtigian, H Katcher, D Parry, G Peters, A Kamb Cancer Res 55, 2988–2994 (1995).
10.1128/mcb.13.7.4107-4114.1993 · DOI
P W Hinds, C A Finlay, R S Quartin, S J Baker, E R Fearon, B Vogelstein, A J Levine Cell Growth Diff 1, 571–580 (1990).
10.1128/mcb.7.8.2745-2752.1987 · DOI
10.1126/science.256.5058.827 · DOI
10.1128/mcb.2.9.1044-1051.1982 · DOI
G Shaulsky, N Goldfinger, M S Tosky, A J Levine, V Rotter Oncogene 6, 2055–2065 (1991).

Sorted by citations

Items 301–400 of 896

Obligate Roles for p16 Ink4a and p19 Arf -p53 in the Suppression of Murine Pancreatic Neoplasia
Bardeesy, N. M., Morgan, J. A., Sinha, M., Signoretti, S., Srivastava, S., Loda, M. F., Merlino, G. T., & DePinho, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.2.635-643.2002 · Cited by 74
Ultraviolet Radiation Induces Phosphorylation and Ubiquitin-Mediated Degradation of ΔNP63α
Westfall, M. D., Joyner, A. S., Barbieri, C. E., Livingstone, M., & Pietenpol, J. A. (2005) · Cell Cycle · doi:10.4161/cc.4.5.1685 · Cited by 74
The p53 tumor suppressor: Critical regulator of life & death in cancer
Fisher, D. E. (2001) · APOPTOSIS · doi:10.1023/a:1009659708549 · Cited by 74
Human p14ARF-mediated cell cycle arrest strictly depends on intact p53 signaling pathways
Weber, H. O., Samuel, T., Rauch, P., & Funk, J. O. (2002) · Oncogene · doi:10.1038/sj.onc.1205429 · Cited by 74
RNA Helicase DDX5 Is a p53-Independent Target of ARF That Participates in Ribosome Biogenesis
Saporita, A. J., Chang, H., Winkeler, C. L., Apicelli, A. J., Kladney, R. D., Wang, J., Townsend, R. R., Michel, L. S., & Weber, J. D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1472 · Cited by 74
Self-citation
Hepatitis B Virus X Protein Differentially Regulates Cell Cycle Progression in X-transforming Versus Nontransforming Hepatocyte (AML12) Cell Lines
Lee, S., Tarn, C., Wang, W., Chen, S., Hullinger, R. L., & ANDRISANI, O. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108025200 · Cited by 73
Aberrant ubiquitin-mediatedproteolysis of cell cycle regulatory proteins and oncogenesis
Bashir, T., & Pagano, M. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)88305-7 · Cited by 73
DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q
Bello, M. J., Amiñoso, C., Lopez-Marín, I., Arjona, D., González‐Gómez, P., Alonso, M. E., Lomas, J., de Campos, J. M., Kusak, M. E., Vaquero, J., et al. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0911-6 · Cited by 73
Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells.
Waheed, I., Guo, Z. S., Chen, G. A., Weiser, T. S., Nguyen, D. M., & Schrump, D. S. (1999) · PubMed · Cited by 73
Loss of nucleolar localization of NAT10 promotes cell migration and invasion in hepatocellular carcinoma
Tan, Y., Zheng, J., Liu, X., Lu, M., Zhang, C., Xing, B., & Du, X. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.047 · Cited by 72
p53 Protein and Pathogenesis of Melanoma and Nonmelanoma Skin Cancer
Benjamin, C. L., Melnikova, V. O., & Ananthaswamy, H. N. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-77574-6_21 · Cited by 73
Reduced Hepatic Tumor Incidence in Cyclin G1–Deficient Mice
Jensen, M. R., Factor, V. M., Fantozzi, A., Helin, K., Huh, C.-G., & Thorgeirsson, S. S. (2003) · Hepatology · doi:10.1053/jhep.2003.50137 · Cited by 70
DNA damage, p14ARF, Nucleophosmin (NPM/B23), and cancer
Gjerset, R. A. (2006) · Journal of Molecular Histology · doi:10.1007/s10735-006-9040-y · Cited by 71
Human Cytomegalovirus IE1-72 Activates Ataxia Telangiectasia Mutated Kinase and a p53/p21-Mediated Growth Arrest Response
Castillo, J., Frame, F. M., Rogoff, H. A., Pickering, M., Yurochko, A. D., & Kowalik, T. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11467-11475.2005 · Cited by 72
Ursodeoxycholic Acid Modulates E2F-1 and p53 Expression through a Caspase-independent Mechanism in Transforming Growth Factor β1-induced Apoptosis of Rat Hepatocytes
Solá, S., Ma, X., Castro, R. E., Kren, B. T., Steer, C. J., & Rodrigues, C. M. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300468200 · Cited by 72
Cytoplasmically “Sequestered” Wild Type p53 Protein Is Resistant to Mdm2-mediated Degradation
Zaika, A. I., Marchenko, N. D., & Moll, U. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27474 · Cited by 72
Cyclin A-CDK Phosphorylation Regulates MDM2 Protein Interactions
Zhang, T., & Prives, C. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011326200 · Cited by 70
pRb and E2f-1 in mouse development and tumorigenesis
Macleod, K. F. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80005-7 · Cited by 70
Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model
Sethi, N. S., Kikuchi, O., Duronio, G. N., Stachler, M. D., McFarland, J. M., Ferrer-Luna, R., Zhang, Y., Bao, C., Bronson, R. T., Patil, D. T., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0574-9 · Cited by 69
Rescue of key features of the p63‐null epithelial phenotype by inactivation of Ink4a and Arf
Su, X., Cho, M. S., Gi, Y. J., Ayanga, B. A., Sherr, C. J., & Flores, E. R. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.151 · Cited by 71
Self-citation
Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis
Carr, M. I., & Jones, S. N. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.75 · Cited by 71
The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2.
Leung, K. M., Po, L. S., Tsang, F. C., Siu, W. Y., Lau, A. W. S., Ho, H. T. B., & Poon, R. Y. C. (2002) · PubMed · Cited by 68
The Genetics and Mechanisms of T-Cell Acute Lymphoblastic LeukemiaPreprint
Gianni, F., Belver, L., & Ferrando, A. A. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035246 · Cited by 69
Head and neck cancer: Response to p53‐based therapeutics
Nemunaitis, J., & Nemunaitis, J. J. (2010) · Head & Neck · doi:10.1002/hed.21364 · Cited by 65
DNA Hypermethylation Status of Multiple Genes in Prostate Adenocarcinomas
Konishi, N., Nakamura, M., Kishi, M., Nishimine, M., Ishida, E., & Shimada, K. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01318.x · Cited by 66
Combined analysis of p53 and RB pathways in epithelial ovarian cancer
Hashiguchi, Y., Tsuda, H., Yamamoto, K., Inoue, T., Ishiko, O., & Ogita, S. (2001) · Human Pathology · doi:10.1053/hupa.2001.27115 · Cited by 67
It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy
Kung, C.-P., & Weber, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818744 · Cited by 71
Self-citation
Association of p14ARF with the p120E4FTranscriptional Repressor Enhances Cell Cycle Inhibition
Rizos, H., Diefenbach, E., Badhwar, P., Woodruff, S., Becker, T. M., Rooney, R. J., & Kefford, R. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210978200 · Cited by 64
Differential p53-Independent Outcomes of p19 Arf Loss in Oncogenesis
Chen, Z., Carracedo, A., Lin, H., Koutcher, J. A., Behrendt, N., Egia, A., Alimonti, A., Carver, B. S., Gerald, W. L., Teruya‐Feldstein, J., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000053 · Cited by 66
The Many Faces of MDM2 Binding Partners
Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 66
p16INK4a promoter methylation and protein expression in breast fibroadenoma and carcinoma
Vinci, A. D., Perdelli, L., Banelli, B., Salvi, S., Casciano, I., Gelvi, I., Allemanni, G., Margallo, E., Gatteschi, B., & Romani, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20771 · Cited by 63
Cytokine response gene 6 induces p21 and regulates both cell growth and arrest
Fan, W., Richter, G. H. S., Cereseto, A., Beadling, C., & Smith, K. A. (1999) · Oncogene · doi:10.1038/sj.onc.1203054 · Cited by 64
CARF Is a Novel Protein That Cooperates with Mouse p19 (Human p14 ) in Activating p53
Hasan, M. K., Yaguchi, T., Sugihara, T., Kumar, P. K. R., Taira, K., Reddel, R. R., Kaul, S. C., & Wadhwa, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204177200 · Cited by 65
Apoptosis Signal-regulating Kinase 1 Is a Direct Target of E2F1 and Contributes to Histone Deacetylase Inhibitorinduced Apoptosis through Positive Feedback Regulation of E2F1 Apoptotic Activity
Tan, J. Y., Zhuang, L., Jiang, X., Yang, K., Karuturi, K. M., & Yu, Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512719200 · Cited by 63
Differential Regulation of E2F1, DP1, and the E2F1/DP1 Complex by ARF
Datta, A., Nag, A., & Raychaudhuri, P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8398-8408.2002 · Cited by 63
Specific Allelic Loss of p16 Tumor Suppressor Gene after Weeks of Iron-Mediated Oxidative Damage during Rat Renal Carcinogenesis
Hiroyasu, M., Ozeki, M., Kohda, H., Echizenya, M., Tanaka, T., Hiai, H., & Toyokuni, S. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64860-2 · Cited by 61
Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression
Ming, Z., Lim, S. Y., & Rizos, H. (2020) · Biomolecules · doi:10.3390/biom10101447 · Cited by 65
A Single Recombinant Adenovirus Expressing p53 and p21-targeting Artificial microRNAs Efficiently Induces Apoptosis in Human Cancer Cells
Idogawa, M., Sasaki, Y., Suzuki, H., Mita, H., Imai, K., Shinomura, Y., & Tokino, T. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2396 · Cited by 62
p14ARF nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways
Sánchez‐Aguilera, A., Sánchez‐Beato, M., García, J. F., Priéto, I., Pollán, M., & Piris, M. A. (2002) · Blood · doi:10.1182/blood.v99.4.1411 · Cited by 62
Germline melanoma susceptibility and prognostic genes: A review of the literature
Ward, K. A., Lazovich, D., & Hordinsky, M. K. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.02.042 · Cited by 64
Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal stresses
Lee, S. H., Kim, J., Kim, Y., Seok, K.-O., Kim, J.-H., Chang, Y.-J., Kang, H.-Y., & Park, J. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.40 · Cited by 59
Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease.
Klump, B., Hsieh, C., Dette, S., Holzmann, K., Kiebetalich, R., Jung, M. F., Sinn, U., Ortner, M., Porschen, R., & Gregor, M. (2003) · PubMed · Cited by 61
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
Traweek, R. S., Cope, B. M., Roland, C. L., Keung, E. Z.-Y., Nassif, E. F., & Erstad, D. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1006959 · Cited by 64
Inactivation of the ARF–MDM-2–p53 pathway in sporadic Burkitt's lymphoma in children
Wilda, M., Bruch, J., Harder, L., Rawer, D., Reiter, A., Borkhardt, A., & Woessmann, W. (2003) · Leukemia · doi:10.1038/sj.leu.2403254 · Cited by 59
Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers
Tokunaga, E., Maehara, Y., Oki, E., Kitamura, K., Kakeji, Y., Ohno, S., & Sugimachi, K. (2000) · Cancer Letters · doi:10.1016/s0304-3835(99)00434-6 · Cited by 60
E4F1: a novel candidate factor for mediating BMI1 function in primitive hematopoietic cellsPreprint
Chagraoui, J., Niessen, S. L., Lessard, J. A., Girard, S., Coulombe, P., Sauvageau, M., Meloche, S., & Sauvageau, G. (2006) · Genes & Development · doi:10.1101/gad.1453406 · Cited by 62
Illuminating p53 function in cancer with genetically engineered mouse models
Garcia, P. B., & Attardi, L. D. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2013.12.014 · Cited by 65
Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase
Vaziri, H., & Benchimol, S. (1999) · Oncogene · doi:10.1038/sj.onc.1203016 · Cited by 59
Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015
McCormick, F. P. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0336 · Cited by 57
Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action
Qin, J., Nag, S. A., Voruganti, S., Wang, W., & Zhang, R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803988910 · Cited by 57
Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer
Koster, R., van Vugt, M. A. T. M., Timmer‐Bosscha, H., Gietema, J. A., & de Jong, S. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.13 · Cited by 58
Testicular germ cell tumours: The paradigm of chemo-sensitive solid tumours
di Pietro, A., de Vries, E. G. E., Gietema, J. A., Spierings, D. C. J., & de Jong, S. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.06.014 · Cited by 57
Bax translocation and mitochondrial fragmentation induced by Helicobacter pylori
Ashktorab, H. (2004) · Gut · doi:10.1136/gut.2003.024372 · Cited by 56
The Physiology of p16INK4A-Mediated G1 Proliferative Arrest
Shapiro, G. I., Edwards, C. D., & Rollins, B. J. (2000) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:33:2:189 · Cited by 57
Mdm2 Mutant Defective in Binding p300 Promotes Ubiquitination but Not Degradation of p53
Zhu, Q., Yao, J., Wani, G., Wani, M. A., & Wani, A. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102634200 · Cited by 57
The role of the transcription factor DP in apoptosis
Hitchens, M. R., & Robbins, P. D. (2003) · APOPTOSIS · doi:10.1023/a:1025586207239 · Cited by 56
p53 ubiquitination by Mdm2: A never ending tail?
Coutts, A. S., Adams, C., & Thangue, N. B. L. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.01.008 · Cited by 56
Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/β-Catenin Pathway Activation
Finch, A. J., Soucek, L., Junttila, M. R., Swigart, L. B., & Evan, G. I. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01745-08 · Cited by 55
MDM2 Mediates p300/CREB-binding Protein-associated Factor Ubiquitination and Degradation
Jin, Y., Zeng, S. X., Lee, H., & Lu, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309916200 · Cited by 56
Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications
Nikliński, J., Niklinska, W. E., Chyczewski, L., Becker, H., & Pluygers, E. (2001) · European Journal of Cancer Prevention · doi:10.1097/00008469-200106000-00004 · Cited by 55
The Human Tumor Suppressor ARF Interacts with Spinophilin/Neurabin II, a Type 1 Protein-phosphatase-binding Protein
Vivo, M., Calogero, R., Sansone, F., Calabrò, V., Parisi, T., Borrelli, L., Saviozzi, S., & Mantia, G. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006845200 · Cited by 57
C-Abl as a modulator of p53
Levav-Cohen, Y., Goldberg, Z., Zuckerman, V., Grossman, T., Haupt, S., & Haupt, Y. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.152 · Cited by 57
Genetic and epigenetic alteration profiles for multiple genes in salivary gland carcinomas
Kishi, M., Nakamura, M., Nishimine, M., Ikuta, M., Kirita, T., & Konishi, N. (2005) · Oral Oncology · doi:10.1016/j.oraloncology.2004.08.004 · Cited by 55
Assay for Ubiquitin Ligase Activity: High-Throughput Screen for Inhibitors of HDM2
Davydov, I. V., Woods, D. B., Safiran, Y. J., Oberoi, P., Fearnhead, H. O., Fang, S., Jensen, J. P., Weissman, A. M., Kenten, J. H., & Vousden, K. H. (2004) · SLAS DISCOVERY · doi:10.1177/1087057104267956 · Cited by 55
Oncogenic transformation and experimental models of human cancer
Anna, C. S. (2007) · Frontiers in bioscience · doi:10.2741/2661 · Cited by 56
Cardiac outflow tract septation failure in Pax3-deficient embryos is due to p53-dependent regulation of migrating cardiac neural crest
Morgan, S. C., Lee, H.-Y., Relaix, F., Sandell, L. J., Levorse, J. M., & Loeken, M. R. (2008) · Mechanisms of Development · doi:10.1016/j.mod.2008.07.003 · Cited by 54
Animal Models of Tumor-Suppressor Genes
Hakem, R., & Mak, T. W. (2001) · Annual Review of Genetics · doi:10.1146/annurev.genet.35.102401.090432 · Cited by 57
The Inhibitory Effect of Intravesical Fisetin against Bladder Cancer by Induction of p53 and Down‐Regulation of NF ‐kappa B Pathways in a Rat Bladder Carcinogenesis Model
Li, J., Qu, W., Cheng, Y., Sun, Y., Jiang, Y., Zou, T., Wang, Z., Xu, Y., & Zhao, H. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12229 · Cited by 54
The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population
Billingsley, K. G., Maynard, C. C., Schwartz, D. L., & Dominitz, J. A. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5 · Cited by 11
Antitumor protein therapy; Application of the protein transduction domain to the development of a protein drug for cancer treatment
Harada, H., Kizaka‐Kondoh, S., & Hiraoka, M. (2006) · Breast Cancer · doi:10.2325/jbcs.13.16 · Cited by 53
Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models
Zhang, Z., Wang, H., Prasad, G., Li, M., Yu, D. S., Bonner, J. A., Agrawal, S., & Zhang, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0245-03 · Cited by 54
Therapeutic targeting of HES1 transcriptional programs in T-ALL
Schnell, S. A., Ambesi‐Impiombato, A., Sánchez-Martín, M., Belver, L., Xu, L., Qin, Y., Kageyama, R., & Ferrando, A. A. (2015) · Blood · doi:10.1182/blood-2014-10-608448 · Cited by 53
The ARF Tumor Suppressor Can Promote the Progression of Some Tumors
Humbey, O., Pimkina, J. S., Zilfou, J. T., Jarník, M., Dominguez‐Brauer, C., Burgess, D. J., Eischen, C. M., & Murphy, M. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2263 · Cited by 53
Methylation of p14 gene in meningiomas and its correlation to the p53 expression and mutation
Amatya, V. J., Takeshima, Y., & Inai, K. (2004) · Modern Pathology · doi:10.1038/modpathol.3800111 · Cited by 53
Pathogenesis of Persistent Hyperplastic Primary Vitreous in Mice Lacking the Arf Tumor Suppressor Gene
Martin, A. C., Thornton, J. D., Liu, J., Wang, X., Zuo, J., Jablonski, M. M., Chaum, E., Zindy, F., & Skapek, S. X. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0349 · Cited by 53
Self-citation
Iron as a target of chemoprevention for longevity in humans
Toyokuni, S. (2011) · Free Radical Research · doi:10.3109/10715762.2011.564170 · Cited by 53
Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes
Soufir, N., Paillerets, B. B., Desjardins, L., Lévy, C., Bombled, J., Gorin, I., Schlienger, P., & Stoppa‐Lyonnet, D. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1005 · Cited by 53
Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma.
Nicholson, S. A., Okby, N. T., Ma, K., Welsh, J. A., McMenamin, M. G., Travis, W. D., Jett, J. R., Tazelaar, H. D., Trastek, V. F., Pairolero, P. C., et al. (2001) · PubMed · Cited by 53
p16INK4a Is Selectively Silenced in the Tumoral Progression of Mycosis Fungoides
Navas, I. C., Algara, P., Mateo, M. S., Martínez, P., García, C., Rodriguez, J. L., Vanaclocha, F., Barrientos, N., Iglesias, L., Sánchez, L., et al. (2002) · Laboratory Investigation · doi:10.1038/labinvest.3780405 · Cited by 51
Nutrition for Healthy Skin
Krutmann, J., & Humbert, P. G. (2010) · Springer eBooks · doi:10.1007/978-3-642-12264-4 · Cited by 82
Dual Role of the Alternative Reading Frame ARF Protein in Cancer
Fontana, R., Ranieri, M., Mantia, G. L., & Vivo, M. (2019) · Biomolecules · doi:10.3390/biom9030087 · Cited by 54
Microbial Regulation of p53 Tumor Suppressor
Zaika, A. I., Wei, J., Noto, J. M., & Peek, R. M. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005099 · Cited by 50
Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents
Youlyouz‐Marfak, I., Gachard, N., Clorennec, C. L., Najjar, I., Baran‐Marszak, F., Reminieras, L., May, E., Bornkamm, G. W., Fagard, R., & Feuillard, J. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402270 · Cited by 50
Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms
Wang, H., Nan, L., Yu, D. S., Lindsey, J. R., Agrawal, S., & Zhang, R. (2002) · Molecular Medicine · doi:10.1007/bf03402011 · Cited by 50
Bcl-xL gain of function and p19ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms
Finch, A. J., Prescott, J. E., Shchors, K., Hunt, A. E., Soucek, L., Dansen, T. B., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.017 · Cited by 49
Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti‐MDM2 Oligonucleotides
Wang, H., Oliver, P. G., Zhang, Z., Agrawal, S., & Zhang, R. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1281.025 · Cited by 50
New approaches for modelling cancer mechanisms in the mouse
Maddison, K., & Clarke, A. R. (2005) · The Journal of Pathology · doi:10.1002/path.1698 · Cited by 49
Viruses and Lymphomas
Pagano, J. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmp020056 · Cited by 49
Impaired Processing of DNA Photoproducts and Ultraviolet Hypermutability With Loss of p16INK4a or p19ARF
Sarkar-Agrawal, P., Vergilis, I., Sharpless, N. E., DePinho, R. A., & Runger, T. M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh307 · Cited by 48
Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis
Moore, L., Venkatachalam, S., Vogel, H., Watt, J. C., Wu, C.-L., Steinman, H., Jones, S. N., & Donehower, L. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206985 · Cited by 48
Aberrant Expression of Tumor Suppressor Proteins in the Ewing Family of Tumors
Maitra, A., Roberts, H., Weinberg, A. G., & Geradts, J. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-1207-aeotsp · Cited by 48
A conserved domain in exon 2 coding for the human and murine ARF tumor suppressor protein is required for autophagy induction
Budina-Kolomets, A., Hontz, R. D., Pimkina, J. S., & Murphy, M. E. (2013) · Autophagy · doi:10.4161/auto.25831 · Cited by 48
The Retinoblastoma Gene Family in Cell Cycle Regulation and Suppression of Tumorigenesis
Dannenberg, J.-H., & te Riele, H. P. J. (2006) · Results and Problems in Cell Differentiation · doi:10.1007/400_002 · Cited by 47
Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe, T., Katayama, Y., Yoshino, A., Komine, C., & Yokoyama, T. (2003) · PubMed · Cited by 46
Promotion of S-phase entry and cell growth under serum starvation by SAG/ROC2/Rbx2/Hrt2, an E3 ubiquitin ligase component: Association with inhibition of p27 accumulation
Duan, H., Tsvetkov, L. M., Liu, Y., Song, Y., Swaroop, M., Wen, R., Kung, H., Zhang, H., & Sun, Y. (2001) · Molecular Carcinogenesis · doi:10.1002/1098-2744(200101)30:1 · Cited by 39
Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors
Yin, D., Xie, D., Hofmann, W., Miller, C. W., Black, K. L., & Koeffler, H. P. (2002) · Oncogene · doi:10.1038/sj.onc.1206031 · Cited by 47
p53, Mdm2, and c‐Myc overexpression is associated with a poor prognosis in aggressive non‐Hodgkin's lymphomas
Pagnano, K. B. B., Vassallo, J., Lorand-Metze, I. G. H., Costa, F. F., & Saad, S. T. O. (2001) · American Journal of Hematology · doi:10.1002/ajh.1084 · Cited by 47
Negative control elements of the cell cycle in human tumors
Adams, P. D., & Kaelin, W. G. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80123-3 · Cited by 46
Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression
Zhou, Y., Nakajima, R., Shirasawa, M., Fikriyanti, M., Zhao, L., Iwanaga, R., Bradford, A. P., Kurayoshi, K., Araki, K., & Ohtani, K. (2023) · Biology · doi:10.3390/biology12121511 · Cited by 52
Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations
Barekati, Z., Radpour, R., Kohler, C., Zhang, B., Toniolo, P. G., Lenner, P., Lv, Q., Zheng, H. Y., & Zhong, X. Y. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq199 · Cited by 46

Authors: Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J.
Affiliations: St. Jude Children's Research Hospital (US)
Howard Hughes Medical Institute and Departments of Tumor Cell Biology and Biochemistry, St. Jude Children’s Research Hospital, 332 North Lauderdale, Memphis, TN 38105
Corresponding author: Sherr, Charles J.
ORCID: Kamijo, Takehiko
Weber, Jason D.
Zambetti, Gerard
Roussel, Martine F.
Sherr, Charles J.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 1998-07-07
Volume: 95
Issue: 14
Pages: 8292-8297
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.95.14.8292
PMC: PMC20969
OpenAlex: W2141529421
Cited by: 899
References: 61
Citations by year: 2026: 5 · 2025: 5 · 2024: 2 · 2023: 10 · 2022: 11 · 2021: 15 · 2020: 10 · 2019: 10 · 2018: 12 · 2017: 14 · 2016: 26 · 2015: 21 · 2014: 33 · 2013: 28 · 2012: 34
FWCI: 31.09
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: St. Jude Children's Research Hospital (CA21765)
American Lebanese Syrian Associated Charities (CA 21765)
National Institutes of Health (CA21765))
National Cancer Institute (R01CA063230, CA-71907, CA-63230, CA21765, P30CA021765, P01CA071907)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: p19ARF, p53, MDM2, INK4a/ARF locus, p16INK4a, protein-protein interaction, p53 stabilization, p21 Cip1, cell cycle arrest, p53-dependent transcription, tumor suppressor, p53 DNA binding, N-terminal domain
MeSH terms: Animals, Humans, Neoplasm Proteins, Nuclear Proteins, Proteins, Proto-Oncogene Proteins, Retroviridae, Transfection, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, 3T3 Cells, Tumor Suppressor Protein p14ARF, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks